Skip to main content

Table 3 RECIST 1.1 response classification at 3 months post-treatment

From: Mode of progression after radioembolization in patients with colorectal cancer liver metastases

Total

No extrahepatic metastases at baseline

 

48(53%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

5 (10%)

13 (27%)

30 (63%)

 

Extrahepatic metastases at baseline

 

42 (47%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

0 (0%)

3 (7%)

39 (93%)*

Yttrium-90 Resin

No extrahepatic metastases at baseline

 

28(61%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

1 (4%)

7 (25%)

20 (71%)

 

Extrahepatic metastases at baseline

 

18 (39%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

0 (0%)

2 (11%)

16 (89%)

Yttrium-90 Glass

No extrahepatic metastases at baseline

 

9 (45%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

2 (22%)

2 (22%)

5 (56%)

 

Extrahepatic metastases at baseline

 

11 (55%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

0 (0%)

0 (0%)

11 (100%)

Holmium-166

No extrahepatic metastases at baseline

 

11 (46%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

2 (18%)

4 (36%)

5 (46%)

 

Extrahepatic metastases at baseline

 

13 (54%)

 

Complete response

Partial response

Stable disease

Progressive disease

0 (0%)

0 (0%)

1 (8%)

12 (92%) *

  1. This table shows a comparison of RECIST 1.1 response classification at 3 months post-treatment for patients with or without extrahepatic metastases at baseline. Numbers represent number of patients (% of total/subcategory)
  2. *Marks significant difference between groups; p < 0.05